U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H10N4O2S
Molecular Weight 250.2785
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFADIAZINE

SMILES

c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N

InChI

InChIKey=SEEPANYCNGTZFQ-UHFFFAOYSA-N
InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/dosage/sulfadiazine.html

Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. Used for the treatment of rheumatic fever and meningococcal meningitis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

7.753536E11
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

7.753536E11
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

7.753536E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
84.9 μg/mL
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.247 μg × h/mL
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.9 h
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Disc. AE: Stenocardia, Distress gastrointestinal...
Other AEs: Thrombopenia, Creatinine serum increased...
AEs leading to
discontinuation/dose reduction:
Stenocardia (grade 3, 5%)
Distress gastrointestinal (grade 3, 5%)
Skin rash (grade 3, 5%)
Other AEs:
Thrombopenia (9%)
Creatinine serum increased (5%)
Elevated liver enzyme levels (5%)
Malaise (23%)
Diarrhea (5%)
Sources: Page: p.36, 38
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Disc. AE: Stevens Johnson syndrome, Thrombocytopenia...
Other AEs: Skin rash, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Stevens Johnson syndrome (grade 3, 1.16%)
Thrombocytopenia (grade 4, 25%)
Major bleed (grade 4, 25%)
Other AEs:
Skin rash (1.16%)
Neutropenia (18.75%)
Febrile neutropenia (1.16%)
Sources: Page: p.4
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Disc. AE: Skin rash, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 3, 17.24%)
Neutropenia (grade 3, 3.45%)
Acute renal failure (grade 3, 6.9%)
Sources: Page: p.476
AEs

AEs

AESignificanceDosePopulation
Malaise 23%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Creatinine serum increased 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Diarrhea 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Elevated liver enzyme levels 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Thrombopenia 9%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Distress gastrointestinal grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Skin rash grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Stenocardia grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Febrile neutropenia 1.16%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Skin rash 1.16%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Neutropenia 18.75%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Stevens Johnson syndrome grade 3, 1.16%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Major bleed grade 4, 25%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Thrombocytopenia grade 4, 25%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Skin rash grade 3, 17.24%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Neutropenia grade 3, 3.45%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Acute renal failure grade 3, 6.9%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 6.65 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
[New trends in ocular toxoplasmosis--the review].
2001
Systematic review of the use of honey as a wound dressing.
2001
Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim (trimazin 30%) after oral administration in non-fasted young pigs.
2001 Aug
Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter.
2001 Aug
Flamazine is not a debriding agent.
2001 Aug 9-Sep 12
[Drug hypersensitivity syndrome rapidly resolving after human immunoglobulin infusion].
2001 Dec
Bullous eruptions caused by extravasation of mannitol--a case report.
2001 Dec
Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections: review.
2001 Dec
Enhanced anti-Shigella activity of erythromycin supplemented with sulfadiazine.
2001 Dec
Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice.
2001 Dec
Development of an artificial dermis preparation capable of silver sulfadiazine release.
2001 Dec 5
Matrix solid-phase dispersion extraction and high-performance liquid chromatographic determination of residual sulfonamides in chicken.
2001 Dec 7
Exposure to liquid sulfur mustard.
2001 Jun
Delayed primary excision and grafting of full thickness alkali burns of the hand and forearm.
2001 Jun
Development of an indirect competitive ELISA for ciprofloxacin residues in food animal edible tissues.
2001 Mar
Inhibition of aerobic growth and nitrification of bacteria in sewage sludge by antibacterial agents.
2001 May
Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose.
2001 May
In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices.
2001 May
2-[N1-2-pyrimidyl-aminobenzenesulfonamido] ethyl 4-bis(2-chloroethyl) aminophenyl butyrate: a potent antitumor agent.
2001 May 7
Burns and injuries resulting from the use of gel candles.
2001 May-Jun
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Clinical microbiological case: visual problems in an HIV-positive patient.
2001 Nov
Winston Churchill and M & B.
2001 Nov
A novel kind of antitumour drugs using sulfonamide as parent compound.
2001 Nov-Dec
In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters.
2001 Oct
Determination of selected sulfonamide antibiotics and trimethoprim in manure by electrospray and atmospheric pressure chemical ionization tandem mass spectrometry.
2002
[A case of primary pyoderma-like aspergillosis occurring in a patient with a cervical spinal cord injury].
2002
Transfer and distribution profiles of dietary sulphonamides in the tissues of the laying hen.
2002 Apr
Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.
2002 Aug
[Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine].
2002 Feb
[Congenital toxoplasmosis: prevention in the pregnant woman and management of the neonate].
2002 Feb
Comparison of propolis skin cream to silver sulfadiazine: a naturopathic alternative to antibiotics in treatment of minor burns.
2002 Feb
Effect of sulphadiazine and trimethoprim on the immune response of rainbow trout (Oncorhynchus mykiss).
2002 Feb
Effects of silver sulphadiazine on the production of exoproteins by Staphylococcus aureus.
2002 Jan
Antimicrobial-impregnated central venous catheters.
2002 Jan
Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats.
2002 Jan
Atypical anterior optic neuropathy caused by toxoplasmosis.
2002 Jan
Complete osseous regeneration of a large skull defect in a patient with cutis aplasia: a conservative approach.
2002 Jul
An update on current practices in the management of ocular toxoplasmosis.
2002 Jul
The effectiveness of processed grapefruit-seed extract as an antibacterial agent: I. An in vitro agar assay.
2002 Jun
Anal canal amputation and necrosis of the anal sphinchter due to electric current injury.
2002 Jun
Laminin modified infection-preventing collagen membrane containing silver sulfadiazine-hyaluronan microparticles.
2002 Jun
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.
2002 Jun
Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs.
2002 Mar
Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery.
2002 Mar 5
[Topical agents used in the treatment of burns].
2002 Mar-Apr
[Glanders--a potential disease for biological warfare in humans and animals].
2002 May
Folate deficiency during treatment with orally administered folic acid, sulphadiazine and pyrimethamine in a horse with suspected equine protozoal myeloencephalitis (EPM).
2002 May
Unsuspected Toxoplasma gondii empyema in a bone marrow transplant recipient.
2002 May 1
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.
2002 May 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Can also be used topically http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=018810&DrugName=THERMAZENE&ActiveIngred=SILVER%20SULFADIAZINE&SponsorApplicant=THEPHARMANETWORK%20LLC&ProductMktStatus=1&goto=Search.DrugDetails
Usual Adult Dose for Toxoplasmosis Toxoplasmic encephalitis: Initial dose: Pyrimethamine 200 mg orally once Maintenance dose: <60 kg: Sulfadiazine 1 g orally every 6 hours plus pyrimethamine 50 mg orally once a day. >=60 kg: Sulfadiazine 1500 mg orally every 6 hours plus pyrimethamine 75 mg orally once a day. In addition, leucovorin 10 to 20 mg/day orally (may increase up to 50 mg/day).
Route of Administration: Oral
Sulfadiazine inhibited Pseudomonas aeruginosa with MIC 256 ug/mL
Name Type Language
SULFADIAZINE
EP   GREEN BOOK   INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
SULFADIAZINE [ORANGE BOOK]
Common Name English
SDZ
Common Name English
SULFADIAZINE COMPONENT OF SULFONAMIDES DUPLEX
Common Name English
TRISULFAPYRIMIDINES (SULFADIAZINE) [ORANGE BOOK]
Common Name English
SULFADIAZINE [INN]
Common Name English
SULFADIAZINE [USP]
Common Name English
NEOTRIZINE COMPONENT SULFADIAZINE
Common Name English
SULFACOMBIN
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-2-PYRIMIDINYL-
Systematic Name English
N(SUP 1)-2-PYRIMIDINYLSULFANILAMIDE
Systematic Name English
SULFADIAZINE COMPONENT OF LANTRISUL
Common Name English
SULFADIAZINE [GREEN BOOK]
Common Name English
SULFADIAZINE COMPONENT OF NEOTRIZINE
Common Name English
SULFADIAZINE [JAN]
Common Name English
SULFADIAZINE COMPONENT OF TRIPLE SULFOID
Common Name English
TRIPLE SULFOID COMPONENT SULFADIAZINE
Common Name English
SULFADIAZINE [WHO-DD]
Common Name English
TERFONYL COMPONENT SULFADIAZINE
Common Name English
COCO-DIAZINE
Brand Name English
SULFADIAZINE COMPONENT OF TERFONYL
Common Name English
SULFALOID COMPONENT SULFADIAZINE
Common Name English
SULFADIAZINE [USP MONOGRAPH]
Common Name English
SULFONAMIDES DUPLEX COMPONENT SULFADIAZINE
Common Name English
SULFOSE COMPONENT SULFADIAZINE
Common Name English
SULPHADIAZINE
Common Name English
LANTRISUL COMPONENT SULFADIAZINE
Common Name English
SULFADIAZINE COMPONENT OF SULFOSE
Common Name English
SULFADIAZINE [VANDF]
Common Name English
SULFADIAZINE COMPONENT OF SULFALOID
Common Name English
SULFADIAZINE [MART.]
Common Name English
SULFADIAZINE [EP MONOGRAPH]
Common Name English
SULFADIMIDINE IMPURITY B [EP]
Common Name English
SULFADIAZINE [USP-RS]
Common Name English
TRISULFAPYRIMIDINES (SULFADIAZINE)
Common Name English
SULFADIAZINE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01EW10
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
LIVERTOX 906
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
WHO-ATC J01EC02
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
CFR 21 CFR 520.2611
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
WHO-ATC J01EE06
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
CFR 21 CFR 520.2610
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
WHO-VATC QJ01EQ10
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
CFR 21 CFR 520.2215
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
CFR 21 CFR 520.2613
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
CFR 21 CFR 520.2612
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
FDA ORPHAN DRUG 78093
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
WHO-ATC J01EE02
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
WHO-VATC QJ51RE01
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.4
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
CFR 21 CFR 522.2610
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
NDF-RT N0000175503
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
NCI_THESAURUS C29739
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
Code System Code Type Description
MERCK INDEX
M10305
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY Merck Index
FDA UNII
0N7609K889
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
MESH
D013411
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
WIKIPEDIA
SULFADIAZINE
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
ChEMBL
CHEMBL439
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
EVMPD
SUB10695MIG
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
CAS
68-35-9
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
PUBCHEM
5215
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
NCI_THESAURUS
C29468
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
INN
421
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-685-8
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
RXCUI
10171
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY RxNorm
EPA CompTox
68-35-9
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
USP_CATALOG
1625009
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB00359
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY
DRUG CENTRAL
2500
Created by admin on Fri Jun 25 20:57:50 UTC 2021 , Edited by admin on Fri Jun 25 20:57:50 UTC 2021
PRIMARY